Researchers from Adicet Bio Inc. reported on the preclinical development of ADI-925, an engineered Chimeric Adapter (CAd) γδ1 T-cell therapy that targets major histocompatibility complex class I chain-related protein A/B (MICA/MICB) and ULBP1-6 expressed in tumor cells.